IMATINIB

Course overview

IMATINIB IS A MEDICATION USED IN THE MANAGEMENT AND TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA, GASTROINTESTINAL STROMAL TUMORS, AND OTHER MALIGNANCIES. IT IS IN THE TYROSINE-KINASE INHIBITORS CLASS OF DRUGS. THIS ACTIVITY REVIEWS THE INDICATIONS, ACTION, AND CONTRAINDICATIONS FOR IMATINIB AS A VALUABLE AGENT IN THE TREATMENT OF SEVERAL ONCOLOGIC INDICATIONS. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., DOSING, ADMINISTRATION, MONITORING, RELEVANT INTERACTIONS, AND TOXICITY) PERTINENT FOR MEMBERS OF THE HEALTHCARE TEAM FOR TREATING PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA, GASTROINTESTINAL STROMAL TUMORS, AND OTHER RELATED CONDITIONS.